Biogen Canada Inc. requests that the previous CADTH-recommended criteria (see project SR0576-000) for Spinraza be expanded to include adult type II & type III patients older than 18 years of age regardless of ambulatory status.
Spinraza (nusinersen) is indicated for the treatment of 5q Spinal Muscular Atrophy (SMA).
Do not reimburse
The requested reimbursement criteria are provided by the applicant and do not
the views of CADTH. Reimbursement criteria from CADTH will be documented in the final
recommendation, if applicable.
Call for patient/clinician input open
Call for patient/clinician input closed
- Patient input submission received from Cure SMA Canada, Muscular Dystrophy Canada and The Love for Lewiston Foundation
Draft CADTH review report(s) provided to sponsor for comment
Deadline for sponsors comments
CADTH review report(s) and responses to comments provided to sponsor
Expert committee meeting (initial)
Draft recommendation issued to sponsor
Draft recommendation posted for stakeholder feedback
End of feedback period
- Reconsideration: major revisions requested by sponsor
Expert committee meeting
Final recommendation issued to sponsor and drug plans
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)